stockrowPfizer Inc.
PFE Healthcare Drug Manufacturers General
Pfizer Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.6 billion, down 1.65% from fiscal 2024.
- Revenue
- −0.43%
- EPS
- −7.98%
- Free cash flow
- +20.0%
- Total debt
- +1.55%
Quarter to September 2026, against a year earlier
Follow PFE
Alert me
Pfizer Inc. (PFE) Gross margin
Pfizer Inc.'s gross margin over the twelve months to 30 September 2026 was 73.4%, down 0.9 percentage points from fiscal 2025 (74.3%). Over the past ten years it has ranged from 58.1% (fiscal 2023) to 80.3% (fiscal 2019); the current reading is higher than 45% of that period. That is in line with the Drug Manufacturers General industry median of 73.0% and above the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 74.3% | 2.39 |
| FY2024 | 71.9% | 13.84 |
| FY2023 | 58.1% | (7.95) |
| FY2022 | 66.1% | 3.97 |
| FY2021 | 62.1% | (17.55) |
| FY2020 | 79.6% | (0.68) |
| FY2019 | 80.3% | 2.32 |
| FY2018 | 78.0% | (0.64) |
| FY2017 | 78.6% | 1.96 |
| FY2016 | 76.7% | (3.58) |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Sep 2026 | 75.7% | 2.93 |
| Jun 2026 | 72.8% | (2.67) |
| Mar 2026 | 75.5% | 5.48 |
| Dec 2025 | 70.0% | (4.98) |
| 43 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| AZN AstraZeneca PLC compare | 81.9% |
| NVO Novo Nordisk A/S compare | 80.7% |
| GILD Gilead Sciences, Inc. compare | 79.9% |
| NVS Novartis AG compare | 74.9% |
| SNY Sanofi compare | 73.4% |
| PFE Pfizer Inc. | 73.4% |
| GSK GSK PLC Sponsored ADR compare | 72.6% |
| AMGN Amgen Inc. compare | 70.9% |
| BMY Bristol Myers Squibb Company compare | 69.2% |
| Drug Manufacturers General industry median | 73.0% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on PFE
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement